Revenue
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
West Pharmaceutical Services Inc (WST)
Price$341.37Cached quote
Net income
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B | $2.15B | $1.84B | $1.72B | $1.60B | $1.51B | $1.40B | $1.42B | $1.37B | $1.27B | $1.19B | $1.10B | $1.06B | $1.05B |
| Gross profit | $1.10B | $998.5M | $1.13B | $1.14B | $1.18B | $767.8M | $605.7M | $545.4M | $512.9M | $501.4M | $455.8M | $447.8M | $434.7M | $387.7M | $339.3M | $318.1M | $303.6M | $302.6M |
| Gross margin | 35.91% | 34.51% | 38.28% | 39.36% | 41.52% | 35.76% | 32.92% | 31.76% | 32.07% | 33.23% | 32.56% | 31.50% | 31.77% | 30.61% | 28.46% | 28.80% | 28.76% | 28.79% |
| Research & development | $74.3M | $69.1M | $68.4M | $58.5M | $52.8M | $46.9M | $38.9M | $40.3M | $39.1M | $36.8M | $34.1M | $37.3M | $37.9M | $33.2M | $29.1M | $23.9M | $19.9M | $18.7M |
| Operating expenses | $519.1M | $428.6M | $453.2M | $402.2M | $423.5M | $360.9M | $309.1M | $305.1M | $287.1M | $306.2M | $327.2M | $265.8M | $272.3M | $252.6M | $229.7M | $227.4M | $206.1M | $178.5M |
| Operating income | $584.9M | $569.9M | $676.0M | $734.0M | $752.3M | $406.9M | $296.6M | $240.3M | $225.8M | $195.2M | $128.6M | $182.0M | $162.4M | $135.1M | $109.6M | $90.7M | $97.5M | $124.1M |
| Operating margin | 19.03% | 19.70% | 22.92% | 25.43% | 26.57% | 18.95% | 16.12% | 13.99% | 14.12% | 12.93% | 9.19% | 12.80% | 11.87% | 10.67% | 9.19% | 8.21% | 9.24% | 11.81% |
| EBITDA | $756.3M | $725.3M | $813.3M | $854.6M | $874.6M | $516.0M | $400.0M | $344.7M | $322.5M | $285.9M | $218.5M | $272.0M | $247.6M | $212.0M | $185.3M | $163.9M | $165.6M | $180.2M |
| EBITDA margin | 24.60% | 25.07% | 27.57% | 29.60% | 30.89% | 24.03% | 21.74% | 20.07% | 20.17% | 18.95% | 15.61% | 19.14% | 18.09% | 16.74% | 15.54% | 14.84% | 15.69% | 17.14% |
| Net income | $493.7M | $492.7M | $593.4M | $585.9M | $661.8M | $346.2M | $241.7M | $206.9M | $150.7M | $143.6M | $95.6M | $127.1M | $112.3M | $80.7M | $75.5M | $65.3M | $72.6M | $86.0M |
| Net profit margin | 16.06% | 17.03% | 20.12% | 20.30% | 23.37% | 16.13% | 13.14% | 12.05% | 9.42% | 9.52% | 6.83% | 8.94% | 8.21% | 6.37% | 6.33% | 5.91% | 6.88% | 8.18% |
| Basic EPSper basic share | $6.83 | $6.75 | $7.98 | $7.87 | $8.89 | $4.68 | $3.27 | $2.80 | $2.04 | $1.96 | $1.33 | $1.79 | $1.61 | $1.19 | $1.12 | $0.98 | $1.11 | $1.33 |
| Diluted EPSper diluted share | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 | $4.57 | $3.21 | $2.74 | $1.99 | $1.91 | $1.30 | $1.75 | $1.57 | $1.15 | $1.08 | $0.95 | $1.06 | $1.25 |
Owners
Reported shareholders
9.45%of listed shares
BlackRock, Inc.6.65M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 9.45%6.65M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 6.55%4.61M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 5.70%4.02M shares |
FMR LLC | 5.08%3.57M shares |
STATE STREET CORP | 4.76%3.35M shares |
Artisan Partners Limited Partnership | 3.43%2.41M shares |
Bank of New York Mellon Corp | 2.90%2.04M shares |
GENERATION INVESTMENT MANAGEMENT LLP | 2.88%2.03M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.70%1.9M shares |
T. Rowe Price Investment Management, Inc. | 2.56%1.81M shares |
MORGAN STANLEY | 2.25%1.58M shares |
JPMORGAN CHASE & CO | 1.65%1.16M shares |
BROWN ADVISORY INC | 1.53%1.08M shares |
Longview Partners (Guernsey) LTD | 1.47%1.03M shares |
Invesco Ltd. | 1.43%1.01M shares |
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.26%884.87K shares |
NORGES BANK | 1.23%862.92K shares |
GOLDMAN SACHS GROUP INC | 1.16%814.77K shares |
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC | 1.08%760.62K shares |
TD Asset Management Inc | 1.04%731.05K shares |
Percentages use 70.4M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 27, 2026Form 4 | Favorite Annette FSr. VP & Chief HR Officer | SellCommon Stock | 2.8K | $305.20 | $859.7K | 16.8K |
| Apr 27, 2026Form 4 | Winters ChadVP, Chief Accounting Officer | SellCommon Stock | 896 | $300.67 | $269.4K | 1.5K |
| Oct 29, 2024Form 4 | Witherspoon CharlesVP & Treasurer | SellCommon Stock | 225 | $310.40 | $69.8K | 1.3K |
| Oct 29, 2024Form 4 | Witherspoon CharlesVP & Treasurer | SellCommon Stock | 478 | $310.40 | $148.4K | 1.5K |
| Aug 19, 2024Form 4 | Witherspoon CharlesVP & Treasurer | SellCommon Stock | 500 | $300.00 | $150.0K | 1.5K |